Trial Profile

A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination Pembrolizumab Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 08 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Dec 2025 Status changed from active, no longer recruiting to discontinued, according to Genmab media release. This decision reflects prioritization of higher impact opportunities across Genmabs late stage pipeline and increasingly competitive landscape.
06 Nov 2025 Planned End Date changed from 1 Mar 2027 to 27 May 2027.
05 Aug 2024 According to a BioNTech media release, updated data from this ongoing trial is expected to be presented at the 2024 World Conference on Lung Cancer taking place from September 7-10, 2024 in San Diego, California, U.S.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com